Amneal Pharmaceuticals is Built for Growth

2026 J.P. Morgan Healthcare Conference

January 13, 2026

Amneal

Cautionary statement on forward looking statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; anticipated product approvals; expected or estimated operating results and financial performance; and statements regarding our positioning for growth, and other non-historical statements. Words such as "plans," "expects," "will," "anticipates," "estimates," and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our ability to identify, make, and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our class A common stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

This presentation includes certain non-GAAP financial measures, including EBITDA and adjusted EBITDA, which are intended as supplemental measures of the Company's performance that are not required by or presented in accordance with GAAP. Adjusted EBITDA reflects net income (loss) adjusted to exclude (i) interest expense, net, (ii) (benefit from) provision for income taxes, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) acquisition, site closure, and idle facility expenses, (vi) restructuring and other charges, (vii) loss on refinancing (viii) (credits) charges related to legal matters, net, (ix) asset impairment charges, (x) foreign exchange loss (gain), (xi) change in fair value of contingent consideration, (xii) (insurance recoveries) charges for property losses and associated expenses, net, (xiii) regulatory approval of milestone, (xiv) amortization of upfront payment, (xv) (decrease) increase in tax receivable agreement liability, (xvi) reorganization expense, and (xvii) other. Management uses these non-GAAP measures internally to evaluate and manage the Company's operations and to better understand its business because they facilitate a comparative assessment of the Company's operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company's operations and underlying operational performance. The compensation committee of the Company's board of directors also uses certain of these measures to evaluate management's performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company's financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company's financial performance, results of operations and trends while viewing the information through the eyes of management. These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company's financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company's GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included in the appendix, and should not rely on any single financial measure to evaluate the Company's business. A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth herein.



Founded in 2002, Amneal has evolved from a large generics player into a **diversified, global biopharmaceutical leader**.

- **Founded by brothers Chirag and Chintu Patel**, after they saw firsthand the **choice many patients have to make between affording medicine and everything else**
- Driven by the belief that no one should have to face that choice, **Amneal's mission is to improve access to affordable, high-quality and innovative medicine**
- Trusted by healthcare providers and patients, **we deliver a diverse and growing portfolio** of affordable medicines across retail generics, injectables, biosimilars, and specialty branded products

Amneal's mission is to be America's #1 affordable medicines company to expand access to care for everyone.


Access is about more than affordability— it's also about availability, support, and innovation

We work every day to get high-quality medicines into the hands of patients—because **what's the point of innovation if it's not accessible?**



Amneal

Expanding access with a growing portfolio of affordable and innovative medicines



(1) U.S. FDA has awarded Amneal more Competitive Generic Therapy (CGT) product approvals than any other company since the FDA created the approval pathway, as of December 2025. CGT designation is given when there is inadequate generic competition on the market for a specific drug.

Successful transformation and track record: Diversification, growth and deleveraging to create value


	2019	2025[1]
Net Revenues	$1.6B -2%	$3.0 - $3.1B +7% to +11%
Increased Diversification Oral solid generics % of total revenue	53%	25%
Deep Pipeline Pending ANDAs (% non-oral solids) Pipeline products (% non-oral solids) Biosimilars	97 (44%) 80 (64%) 3 pipeline	69 (64%) 44 (95%) 3 commercial + 5 pipeline
Adjusted EBITDA[2]	$339M	$675M - $685M +8% to +9%
Operating Cash Flow	$2M	$300M - $330M
Net Leverage[2]	7.4x	3.7x



(1) Reflects Full Year 2025 Guidance for Net Revenues, Adjusted EBITDA and Operating Cash Flow; Other metrics as of Q3 2025.
(2) Adjusted EBITDA and Net Leverage are non-GAAP measures. Refer to non-GAAP reconciliations in the Q3 2025 earnings presentation.
Note: Growth percentages reflect comparisons to prior year.


Aligned with large, growing U.S. pharmaceutical markets and favorable macro trends

Retail Generics[1]




- Stable pricing environment with growing volumes and less competition per product
- Complex products face fewer rivals and stay longer in market

Injectables[2]




- Provides acute therapies for hospitals amid ongoing market shortages
- U.S. institutional market has less competitors than retail Gx

Biosimilars[3]




- Much greater LOEs in the next decade vs. the prior decade
- U.S. biosimilar adoption is strong (80%+)
- Lower development costs (fewer phase 3) and shorter timelines

Specialty Branded (CNS & Endo)[4]



- Expanding Neurology and Endocrinology markets with therapies for chronic disease
- Requires strong value proposition for brands and clear market access strategy

WW GLP-1 / Peptides[5]



- Strong demand for current class of medicines, still early innings
- New injectables (including combination products) and oral therapies emerging

U.S. Pharma macro trends

69%
U.S. adults on 1 Rx[6]

4+
Average Rx's for 65+ U.S. population[7]

~$234B
Brand products loss of exclusivity 2025-2034[8]

92%
U.S. prescriptions are generics[9]

(1) Estimated U.S. retail market size at the manufacturers level, per management estimates. (2) Estimated U.S. injectables market size for all institutional injectable products per IQVIA as of June 2025. (3) Estimated U.S. biosimilar market based on IQVIA sales data. (4) Estimated U.S. specialty market size for the portion of Central Nervous System (CNS) and Endocrinology (Endo) market that Amneal serves per Future Market Insights, Inc. (through commercial products or pipeline programs). (5) Estimated WW GLP-1/Peptides market size per Grandview Research report for GLP-1 Receptor Agonist Market. (6) Hales CM, Servais J, Martin CB, Kohen D. Prescription drug use among adults aged 40–79 in the United States and Canada. NCHS Data Brief, no 347. Hyattsville, MD: National Center for Health Statistics. 2019. (7) JAMA Intern Med. 2024;184(9):1121-1123. doi:10.1001/jamainternmed.2024.2781. (8) Per IQVIA report: Assessing the Biosimilar Void in the U.S. (Feb 2025). (9) Per IQVIA report: The Use of Medicines in the U.S. 2024, published May 7, 2024

Amneal

Well positioned to deliver sustainable long-term growth

Segment	Key Areas	Strategy for Growth	FY 2024 Revenue	Historical Growth Rate (2020-2024 CAGR)	Long-term Growth Projection[2]
Affordable Medicines[1]	**Retail Generics** **Injectables** **Biosimilars**	**Differentiated portfolio of 280+ mainly complex products:** • **#4 U.S. Retail Generics business** with 20-30 new launches each year and strong quality track record • **Top 10 and growing U.S. injectables business** with new 505(b)(2) injectable products and significant capacity • **Expanding U.S. biosimilars portfolio** with 3 commercial products and 5 more launches expected 2026-2027	$1.685B	+6%	**High single-digits**
Specialty	**Parkinson's** **Endocrinology** **GLP-1 / Peptides**	**Grow specialty branded portfolio focused on Neurology** (CREXONT®, RYTARY® and Breykia® autoinjector), **Endocrinology** (UNITHROID®) and **obesity** (novel injectable and oral therapies with Metsera) with new sites online by 2028	$446M	+6%	**High single-digits**
AvKARE	**Government** **Distribution** **Unit Dose**	**Growth driven by large portfolio** of products and ongoing cadence of **new product launches**, including from Amneal, with a focus on higher value channels	$663M	+23%	**High single-digits**
Total Company		**Diversified portfolio focused on expanding in Specialty, GLP-1, injectables, biosimilars & complex products**	$2.794B	+9%	**High single-digits**

(1) Affordable Medicines includes Retail Generics, Injectables, Biosimilars and International net revenues.
(2) Growth projection reflects the potential outcomes of delivering our long-term strategy and is based on the current macro environment and expected product pipeline launches, among other assumptions.

In Specialty, expect $300-500M U.S. peak sales for CREXONT® for Parkinson's Disease

CREXONT
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
35mg/140mg · 52.5mg/210mg
70mg/280mg · 87.5mg/350mg

Currently treating
22,000+
U.S. PD patients of
~700K patients on CD/LD

CREXONT® on-track to be the Leading Branded Therapy in Parkinson's Disease


Phase 4 interim data shows substantial clinical benefit vs. other therapies

1M+ U.S. Parkinson's Disease (PD) patient population, ~700K on CD/LD therapy, and 90K+ new diagnoses each year(1)

Longest-lasting oral CD/LD formulation available due to innovative formulation combining IR and ER with novel technology designed to target area of absorption in body

Market share at over 3% in one year post launch, tracking well ahead of RYTARY, signaling strong adoption momentum

CREXONT® Prescription Growth (TRx)(2)
(Month Ending)



CREXONT® performance vs. other therapies

(hours)	Increase in Daily "Good On" Time	Reduction in Daily "Off" Time	Increase in "Good On" Time per Dose
IR CD/LD	+3.13	–2.83	+1.86
IR CD/LD + COMT inhibitor	+2.31	–2.36	+0.77
Rytary® (ER CD/LD)	+1.80	–2.57	+0.79

Amneal

(1) Stocchi F et al. Parkinsonism Relat Disord. 2014;20(2):204-211.
(2) Source: IQVIA monthly script data as of month end December 2025.
(3) "Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease," Press Release, December 30, 2025.

Brekiya® (dihydroergotamine mesylate) autoinjector successfully launched in Q4

For the acute treatment of migraine with or without aura and cluster headaches in adults



Migraine & cluster headache prevalence[1]	13% of 332M **~43M**
Patients treated with prescription medication[2]	46% of 43M **~20M**
Patients treated with cGRP for acute migraine	**~883K**
Patients not responding to cGRPs for acute migraine 15%[3]	15% of 883K **~132K**

Potential broad usage among patients who experience severe, treatment-resistant headaches

First and only autoinjector to deliver, launched in 2025

The power of DHE for sustained pain relief [4-8]

- Provides the same powerful medication used in hospitals, in a disposable, **ready-to-use, single-dose autoinjector** [4,8]
- Can be used **at any point during an attack** and may **reduce headache recurrence** [4,6,7]
- Delivers one dose subcutaneously in the thigh, which may be helpful for patients who respond inadequately to oral therapies due to nausea/vomiting, gastroparesis, or delayed dosing [4,8,9]
- Gives patients the ability to self-administer, with **no need for refrigeration, assembly, or priming the device**[4]

Expect $50-100M U.S. peak sales


(1) Cohen F, et al. Headache. 2024. (2) Lipton RB, et al. Neurology. 2002.(3) Ubrelvy® and Nurtec ODT® clinical trial data; ~15% non-response rate estimated from published efficacy results. (4) Brekiya package insert. Amneal Pharmaceuticals, Bridgewater, NJ; 2025. (5) Data on file. Amneal Pharmaceuticals, LLC. (6) Winner P, et al. Arch Neurol. 1996;53:180–184.(7) Mather PJ, et al. Headache. 1991;31:525–532. (8) Silberstein SD, et al. Headache. 2020;60:40–57. (9) Aurora SK, et al. Cephalalgia. 2013;33:408–415. Note: Sustained represents a duration of approximately 24-72 hours and cluster headache results reported using IV administration.

Diversified Affordable Medicines portfolio with complex products


Purposeful Mix Shift
towards a more complex portfolio

Deep Pipeline
with focus on complex products

Affordable Medicines net revenues mix ($'s)



Pipeline mix (# of products)



Expect 20-30 new launches per year

Note: Total may not add due to rounding. Total Addressable market (TAM) are approximate IQVIA (brand + active generics) MAT August 2025 sales. For 2020 and 2021, AvKARE sales of Amneal label products, royalty income and international revenues are included within Affordable Medicines Non-OSD.

In Affordable Medicines, we are in the midst of a significant new product launch phase

	New Product	Dosage Form	Therapeutic Area	Brand	IQVIA[1]	Approval	Launch
	Lenalidomide	Capsule	Hematology / Oncology	Revlimid®	$7.4B(2)	Q1'25	Q1'26
	Rifaximin	Tablet	Gastroenterology	Xifaxan®	$2.8B(2)	Q1'25	Undisclosed
	Mesalamine DR	Tablet	Gastroenterology	Asacol® HD	$101M	Q1'25	Q1'25
	Everolimus	Tablet	Oncology	Afinitor®	$114M	Q1'25	Q1'25
	Prednisolone acetate	Ophthalmic	Ophthalmology	Pred-Forte®	$198M	Q2'25	Q4'25
	Sodium oxybate	Oral solution	Neurology (narcolepsy)	Xyrem®	n/a(3)	Q3'25	Q1'26
	Bimatoprost	Ophthalmic	Ophthalmology	Lumigan®	$684M	Q3'25	Undisclosed
	Risperidone ER	Vial	Psychiatry	Risperdal Consta®	$192M	Q3'25	Q1'26
	Beclomethasone dipropionate	Inhalation	Respiratory (asthma)	QVAR®	$329M	Q4'25	Q1'26
	Iohexol	Vial	Diagnostic	Omnipaque®	$629M(2)	Q4'25	Q1'26
	Cyclosporine	Ophthalmic	Ophthalmology	Restasis®	$2.0B	Q4'25	Q1'26
	Albuterol sulfate	Inhalation	Respiratory (asthma)	ProAir® HFA	$1.6B	Q4'25	Undisclosed
	Denosumab biosimilars	Vial	Osteoporosis/Bone Cancer	PROLIA® & XGEVA®	$5.3B	Q4'25	Undisclosed
Approved	Epinephrine (2 presentations)	SDV/MDV	Emergency/Critical Care	Adrenalin®	$195M	Q4'25	Q4'25-Q1'26
Pending	Romidepsin injection	Vial	Oncology	Romidepsin	$76M	Q1'26(4)	Q1'26
	Eltrombopag	Tablet	Hematology	Promacta®	$1.3B	Q1'26(4)	Q1'26
	Lanreotide injection	PFS	Endocrinology/Oncology	Somatuline® Depot	$989M	Q2'26(4)	Q2'26
	Epinephrine (3rd presentation)	PFS	Emergency/Critical Care	Adrenalin®	$195M	Q2'26(4)	Q2'26
	Sodium Bicarbonate	IV Bag	Critical Care	Neut®	$115M	Q2'26(4)	Q2'26
	Omalizumab biosimilar	PFS	Immunology/Allergy	XOLAIR®	$4.2B	Q4'26(4)	Undisclosed

Note: Selected new product launches listed. Additional opportunities not disclosed. All trademarks are the property of their respective owners.
PFS = Prefilled Syringe; MDV = Multiple-dose vial; RTU = Ready-to-use; SDV = Single-dose vial; BLA = Biologics License Application.

(1) Reflects trailing twelve months sales per IQVIA as of the most recent period.
(2) Market size reflects the total market across all approved indications. Our product is approved for a subset of these indications.
(3) Distributed through Specialty Pharmacy, not captured in IQVIA.
(4) Not yet approved, estimated approval date.

Amneal

Biosimilars represents the next wave of affordable medicines in the U.S.



Growing U.S. adoption of biosimilars

80%+ conversion to biosimilars typically which improves access to critical therapies and driving substantial cost savings to health system



Shorter timelines to develop and lowering costs

Proposed update to U.S. FDA guidance can reduce need for Phase 3 clinical trials reducing timelines by a few years and cut development costs in half



Increased wave of biologic LOEs over next decade

LOE opportunity grows from ~$36B (2015–2024) to ~$234B (2025–2034), driven by 118 biologics and only ~10% with biosimilar development(1)



Limited number of biosimilar players expected

Only 3-5 competitors expected per molecule going forward, given complexity, cost & development timelines and market dynamics

(1) Per IQVIA report: Assessing the Biosimilar Void in the U.S. (Feb 2025)
Note: LOE = Loss of Exclusivity

Amneal Biosimilars portfolio and pipeline is well-positioned for growth

PRODUCT NAME **Biosimilar** Biologic brand	Therapeutic Area	U.S. Market size(1)	Status
ALYMSYS® **Bevacizumab-maly** Avastin®	Oncology	$1.2B	Commercial
RELEUKO® **Filgrastim-ayow** NEUPOGEN	Oncology	$0.4B	Commercial
FYLNETRA® **Pegfilgrastim-pbbk** Neulasta®	Neutropenia	$0.8B	Commercial
BONCRESA™ **Denosumab-mobz** Prolia®	Osteoporosis	$2.9B	Approved – to be launched
OZILTUS™ **Denosumab-MOBZ** XGEVA®	Bone cancer	$1.5B	Approved – to be launched
Pegfilgrastim OBI & AI Neulasta®	Neutropenia	$0.8B	Q1'26 sBLA filing expected
Omalizumab XOLAIR®	Asthma & Allergies	$4.2B	BLA submitted

Initial portfolio of 6 biosimilars across 8 presentations by 2027

Our biosimilar strategy

- **Initial biosimilars added through in-licensing and establishing commercial platform**
- **Strategic goal is to be vertically integrated across development, manufacturing and commercial, with a consistent cadence of new launches globally**

XOLAIR® represents a significant potential growth catalyst in our Biosimilars portfolio in the coming years




Note: Selected new product launches listed. Additional opportunities not disclosed. All trademarks are the property of their respective owners.
PFS = Prefilled Syringe; MDV = Multiple-dose vial; RTU = Ready-to-use; SDV = Single-dose vial; BLA = Biologics License Application.
(1) Reflects trailing twelve months sales per IQVIA as of August 2025. Market size reflects the total market across all approved indications. Our product is approved for a subset of these indications.

Strategic collaboration with Metsera to drive innovation at scale in the GLP-1 space

Note: Pfizer acquired Metsera on November 13, 2025.

Global Obesity and Metabolic Disease Market 2024-2030(1)



Metsera + Amneal

- Deep expertise in complex drug development & manufacturing;
- Strong track record of delivering quality and innovation at scale
- Trusted developer, manufacturer and distributor of diverse portfolio of 290+ pharmaceutical products
- Extensive in-house capabilities, including API and sterile fill-finish manufacturing

Amneal is uniquely positioned to be a trusted and collaborative partner because of our expertise, scale and speed

Development

Amneal has extensive capabilities from formulation design, peptide chemistry, drug-device development and CMC activities with **over 1,000 scientists**

Manufacturing


Constructing two new, world-class, large-volume manufacturing facilities for peptide synthesis and sterile fill-finish production, and leverage existing Amneal manufacturing sites

Commercialization

- **Metsera's preferred & majority supplier** in U.S., Europe and other markets
- Amneal granted **license to commercialize in 18 emerging markets, including India**

(1) Estimated global GLP-1 market size per Grand View Research GLP-1 Receptor Agonist Market Size 2025 – 2030.
Note: CMC = Chemical, manufacturing and control.

Strong and sustainable top and bottom-line growth expected to continue going forward



Net Revenue +11%
from 2019 to 2024 CAGR

Adjusted EBITDA +13%
from 2019 to 2024 CAGR

Note: Totals may not add due to rounding.
(1) Affordable Medicines includes Retail Generics, Injectables, Biosimilars and International net revenues.
(2) New launches reflects new product launches since 2019 and biosimilars.
(3) Adjusted EBITDA is a non-GAAP measure. Refer to the non-GAAP reconciliation in the Q3 2025 earnings presentation for prior year adjusted EBITDA.

Amneal

Amneal is well positioned to lead and be America's #1 affordable medicines company



A bold company with a clear mission

Advancing our mission to be a leading accessible and affordable medicines company that creates meaningful value for patients, providers and investors

- Strategy anchored in expanding access across therapeutic areas and delivery systems—improving standards of care and delivering substantial value to the healthcare system



A diversified and growing portfolio across key areas

Expanding pharmaceutical portfolio across Complex Generics, Injectables, GLP-1, Biosimilars and Specialty Branded medicines

- Momentum across key areas including Specialty with CREXONT®, Biosimilars with expanding portfolio, and meaningful wave of new high-value launches in Affordable Medicines (Complex Gx and Injectables)



A vision geared towards substantial growth and impact

Positioned for long-term growth with multiple key drivers across large and expanding markets

- Looking forward, no shortage of growth drivers including Specialty, Biosimilars, Injectables & GLP-1

Amneal

Note: Growth percentages reflect comparisons to prior year.

Ameal